Cadrenal Therapeutics announced that its Phase 2 clinical trial data for CAD-1005, a novel 12-lipoxygenase inhibitor targeting Heparin-Induced Thrombocytopenia (HIT), will be presented orally at the ISTH 2026 Congress in Paris. This trial is the first randomized, blinded, placebo-controlled study in HIT, a serious immune-related blood clotting disorder caused by heparin. CAD-1005 aims to address the underlying immune mechanism of HIT, potentially shifting treatment paradigms and targeting a market with up to $2 billion annual revenue potential. The company is preparing to advance CAD-1005 to Phase 3 trials, highlighting its commercial and clinical significance.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Viasat and BMW Group have successfully demonstrated the first integrated automotive satellite voice call, allowing drivers to make calls directly through the car's infotainment system even in areas without cellular coverage. This advancement, utilizi...
Iran has warned it will retaliate fiercely if the US targets its infrastructure, following President Trump's threat to strike Iranian power plants and bridges next week if negotiations fail. The US recently conducted airstrikes against Iranian milita...
Solana (SOL) maintains its price in the mid-$70 range, supported by several key developments. These include Circle's recent issuance of $500 million in USDC on the Solana network, increasing liquidity and transactional demand. Additionally, instituti...
